Khiron's Announces Resignation of Chief Financial Officer Swapan Kakumanu of RTB LLP appointed as Interim CFO
Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF) announced the resignation of Chief Financial Officer Joel Friedman for personal reasons, effective October 31, 2021. Swapan Kakumanu of RTB LLP has been appointed as Interim CFO. Khiron's CEO, Alvaro Torres, expressed gratitude for Friedman's contributions and leadership. Khiron operates in Latin America and Europe, focusing on medical cannabis with a presence in countries like Colombia, Peru, and Germany, and aims to expand into Mexico this year.
- Swapan Kakumanu brings over 25 years of senior finance experience, providing strong leadership during the transition.
- The resignation of the CFO may raise concerns about continuity in financial leadership.
TORONTO, Oct. 1, 2021 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF)(Frankfurt: A2JMZC), a vertically integrated medical cannabis leader with core operations in Latin America and Europe, today announced that Joel Friedman, has resigned as Chief Financial Officer of the Company for personal reasons. Khiron's board of directors has appointed Swapan Kakumanu of RTB LLP to the role of Interim CFO, effective immediately. Mr. Friedman will remain with Khiron until October 31, 2021 to provide transitional support.
Mr. Alvaro Torres, Khiron CEO and Director, commented: "On behalf of the Board of Directors and the management team, I would like to thank Joel for his contributions and leadership to our strong finance team and wish him the best in his future endeavours."
About RTB and Swapan Kakumanu
RTB LLP (www.rtbllp.ca) is a fractional CFO, controller and accounting services provider for private, publicly-traded and non-profit organizations, with a team of accounting professionals with extensive industry experience. Mr. Kakumanu has more than 25 years of senior finance and operations experience and has served at the senior executive management levels, both in public and private companies, in high growth technology, manufacturing, blockchain, medical device, and oil field services industries. He has held senior roles as President, Chief Executive Officer, Chief Financial Officer, Controller, Company Secretary, and Board Member for public and private companies.
About Khiron Life Sciences Corp.
Khiron is a leading vertically integrated medical cannabis company with core operations in Latin America and Europe. Leveraging wholly-owned medical health centres and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific expertise, product innovation, and agricultural infrastructure to drive prescriptions and brand loyalty with patients worldwide. The Company has a sales presence in Colombia, Peru, Germany, UK, and Brazil and is positioned to commence sales in Mexico in 2021. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and diverse executive team and Board of Directors.
Visit Khiron online at investors.khiron.ca and on Instagram @khironlife.
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking information" and "forward-looking statements" within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron's control, including the risk factors discussed in Khiron's Annual Information Form which is available on Khiron's SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and is made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
View original content to download multimedia:https://www.prnewswire.com/news-releases/khirons-announces-resignation-of-chief-financial-officer-swapan-kakumanu-of-rtb-llp-appointed-as-interim-cfo-301390135.html
SOURCE Khiron Life Sciences Corp.
FAQ
What prompted Joel Friedman's resignation as CFO of Khiron Life Sciences Corp?
Who has been appointed as the Interim CFO of Khiron Life Sciences?
How long will Joel Friedman remain with Khiron after his resignation?
What is the impact of the CFO resignation on Khiron Life Sciences stock?
What are Khiron's core operations?
In which countries does Khiron Life Sciences have a sales presence?
